Vargatef in 2nd-line therapy of advanced or metastatic adenocarcinoma of the lung (VARGADO)First published 14/03/2016 Last updated 04/07/2024 EU PAS number: EUPAS12795StudyOngoing
Boehringer Ingelheim Pharma GmbH Boehringer Ingelheim Pharma GmbHStudy contactinfo@boehringer-ingelheim.com